Analgesic efficacy, adverse effects, and safety of oxycodone administered as continuous intravenous infusion in patients after total hip arthroplasty
Authors Olczak B, Kowalski G, Leppert W, Zaporowska-Stachowiak I, Wieczorowska-Tobis K
Received 22 October 2016
Accepted for publication 2 March 2017
Published 4 May 2017 Volume 2017:10 Pages 1027—1032
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 4
Editor who approved publication: Dr Michael Schatman
BogumiĹ‚ Olczak,1 Grzegorz Kowalski,1,2 Wojciech Leppert,2 Iwona Zaporowska-Stachowiak,3 Katarzyna Wieczorowska-Tobis2
1Department of Anesthesiology, Józef StruĹ› Multiprofile Municipal Hospital, 2Department of Palliative Medicine, Poznan University of Medical Sciences, 3Department of Pharmacology, Poznan University of Medical Sciences, Poland
Background: Total hip arthroplasty (THA) causes extensive tissue damage and severe pain. This study aimed to assess the analgesic efficacy, adverse effects (AEs), and safety of continuous intravenous (iv) oxycodone infusion with ketoprofen (injected into the iv line) in patients after THA, and to assay serum oxycodone levels.
Patients and methods: Fourteen patients, aged 59â€’82 years with American Society of Anesthesiologists (ASA) classification I or III, underwent THA with intrathecal analgesia and sedation induced by iv propofol. After the surgery, oxycodone (continuous iv infusion) at a dose of 1 mg/h (five patients) or 2 mg/h (nine patients) with 100 mg ketoprofen (injected into the iv line) was administered to each patient every 12 h. Pain was assessed using a numerical rating scale (NRS: 0 – no pain, 10 – the most severe pain) at rest and during movement. AEs, including hemodynamic unsteadiness, nausea, vomiting, pruritus, cognitive impairment, and respiratory depression, were registered during the first 24 h after surgery.
Results: Oxycodone (continuous iv infusion) at a dose of 2 mg/h with ketoprofen (100 mg) administered every 12 h provided satisfactory analgesia in all nine patients without the need of rescue analgesics within the first 24 h after THA. In three out of five patients, oxycodone at 1 mg/h was effective. Oxycodone did not induce drowsiness, vomiting, pruritus, respiratory depression, or changes in blood pressure. Bradycardia appeared in two patients, and nausea was observed in one patient.
Conclusion: Oxycodone infusion with ketoprofen administered by iv is effective in patients after THA. Intravenous infusion of oxycodone is a predictable, stable, and safe method of drug administration.
Keywords: adverse effects, analgesia, opioid, oxycodone, pain
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Analgesic efficacy and safety of epidural oxycodone in patients undergoing total hip arthroplasty: a pilot study
Olczak B, Kowalski G, Leppert W, Bienert A, TeĹĽyk A, Adamski M, Rzymski S, Wieczorowska-Tobis K
Published Date: 27 September 2017
A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D
Published Date: 22 August 2017
Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain
Leppert W, Kowalski G
Published Date: 4 December 2015
Published Date: 16 April 2015
Quality of life assessment in advanced cancer patients treated at home, an inpatient unit, and a day care center
Leppert W, Majkowicz M, Forycka M, Mess E, Zdun-Ryzewska A
Published Date: 8 May 2014
Published Date: 30 September 2010